Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 2/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 4/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.37 |
| ▸ | NTMT1 | Q9BV86 | 2/20 | 0.37 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.37 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21350918 | 0.91 | ITGB1 (0.41) | ITGB1ITGA4RENAPLNRACE | |
| SCHEMBL21167115 | 0.91 | ITGB1 (0.44) | ITGB1ITGA4RENAPLNRACE | |
| SCHEMBL21166964 | 0.87 | APLNR (0.43) | ITGB1ITGA4RENAPLNRACE | |
| SCHEMBL22478892 | 0.87 | ITGB1 (0.44) | ITGB1ITGA4RENAPLNRACE | |
| SCHEMBL21350667 | 0.84 | REN (0.41) | ITGB1ITGA4RENAPLNRACE | |
| SCHEMBL21166989 | 0.83 | ACE (0.45) | ITGB1ITGA4RENAPLNRACE | |
| SCHEMBL21166966 | 0.81 | ITGB1 (0.44) | ITGB1ITGA4RENAPLNRACE | |
| SCHEMBL21166957 | 0.81 | ACE (0.43) | ITGB1ITGA4RENACEF2 | |
| SCHEMBL21166965 | 0.79 | ITGB1 (0.42) | ITGB1ITGA4RENAPLNRACE | |
| SCHEMBL21167022 | 0.79 | APLNR (0.46) | ITGB1ITGA4APLNRACEF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401943-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN AGONIST RECEPTOR OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2021-12-30 | — | — | US | disclosed |
| US-20210386830-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2021-12-16 | — | — | US | disclosed |
| US-11191812-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | ADOCIA (FR) | 2021-12-07 | — | — | US | disclosed |
| US-11129877-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid | ADOCIA (FR) | 2021-09-28 | — | — | US | disclosed |
| US-20200306379-A1 | INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | ADOCIA (FR) | 2020-10-01 | — | — | US | disclosed |
| US-20190328842-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN AGONIST RECEPTOR OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2019-10-31 | — | — | US | disclosed |
| US-20190275109-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190216931-A1 | INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | ADOCIA (FR) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11191812-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | GCG, GIPR, GLP1R | ITGB1 4576/4885ITGA4 4207/4885REN 558/4885 |
| US-20190275109-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | GCG, GIPR, GLP1R | ITGB1 4540/4885ITGA4 4206/4885REN 715/4885 |
| US-11129877-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid | IAPP, GLP1R, INSR | ITGB1 3600/4885ITGA4 3326/4885REN 506/4885 |
| US-20200306379-A1 | INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | IAPP, INSR, IGFBP5 | ITGB1 3057/4885ITGA4 2236/4885REN 1165/4885 |
| US-20190216931-A1 | INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | IAPP, INSR, IGFBP5 | ITGB1 3057/4885ITGA4 2236/4885REN 1165/4885 |
| US-20190328842-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN AGONIST RECEPTOR OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | IAPP, GLP1R, INSR | ITGB1 3600/4885ITGA4 3326/4885REN 506/4885 |
| US-20210386830-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | GCG, GIPR, GLP1R | ITGB1 4576/4885ITGA4 4207/4885REN 558/4885 |
| US-20210401943-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN AGONIST RECEPTOR OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | IAPP, GLP1R, INSR | ITGB1 3600/4885ITGA4 3326/4885REN 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.